# Administration of Basiliximab

**DOCUMENT NUMBER:** PBMT-GEN-049  
**DOCUMENT TITLE:** Administration of Basiliximab  
**DOCUMENT NOTES:**

<table>
<thead>
<tr>
<th><strong>Document Information</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revision:</strong> 06</td>
<td><strong>Vault:</strong> PBMT-General-rel</td>
</tr>
<tr>
<td><strong>Status:</strong> Release</td>
<td><strong>Document Type:</strong> General</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Date Information</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Creation Date:</strong> 31 Oct 2018</td>
<td><strong>Release Date:</strong> 01 Dec 2018</td>
</tr>
<tr>
<td><strong>Effective Date:</strong> 01 Dec 2018</td>
<td><strong>Expiration Date:</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Control Information</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author:</strong> MOORE171</td>
<td><strong>Owner:</strong> MOORE171</td>
</tr>
<tr>
<td><strong>Previous Number:</strong> PBMT-GEN-049 Rev 05</td>
<td><strong>Change Number:</strong> PBMT-CCR-207</td>
</tr>
</tbody>
</table>
PBMT-GEN-049
ADMINISTRATION OF BASILIXIMAB

1 PURPOSE
1.1 To outline the procedure required for administration of basiliximab. Responsibilities of the nursing staff for administering and monitoring adverse reactions to basiliximab are described.

2 INTRODUCTION
2.1 Basiliximab is a chimeric (murine/human) monoclonal antibody produced by recombinant DNA technology that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor (known as CD25 antigen) on the surface of activated T-lymphocytes.
2.2 Basiliximab is used to treat GVHD in combination with other medications (cyclosporine, tacrolimus, steroids, mycophenolate, azathioprine, etc.).
2.3 The benefits of basiliximab therapy include no myelosuppression and no increased risk of malignancies or lymphoma.

3 SCOPE AND RESPONSIBILITIES
3.1 Interdisciplinary: Attending physicians, advanced practice providers, pharmacists and registered nurses (RN) are all responsible for ensuring that this procedure is carried out.

3.1.1 The nurse is responsible for administration of basiliximab, management of side effects and assessment of response. The nurse may administer basiliximab after successful completion of hospital required medication administration test, chemotherapy test and demonstration of clinical competency with their preceptor.

3.1.2 The physician and advanced practice providers are responsible for ordering medication, assessment and direction of management of patient.

3.1.3 Requires an order from a physician or designee in the electronic medical record

4 DEFINITIONS/ACRONYMS
4.1 D5W Dextrose 5% in Water
4.2 DNA Deoxyribonucleic acid
4.3 GVHD Graft versus host disease
4.4 RN Registered Nurse

5 MATERIALS
5.1 Basiliximab prepared by pharmacy for infusion
5.2 Secondary tubing if medication is in a bag
5.3 Alcohol prep pad
5.4 Cardiac monitor leads
5.5 Pulse Oximeter

6 EQUIPMENT
6.1 Volumetric or Syringe Pump
6.2 Cardiac Monitor with a pulse oximeter

7 SAFETY
7.1 NA

8 PROCEDURE
8.1 Patient Assessment:
8.1.1 Assess intravenous access device for leakage, patency, and blood return.
8.1.2 Assess central venous access site for redness, swelling, drainage and pain.
8.1.3 Severe acute (onset within 24hrs) infusion-related hypersensitivity reactions, including anaphylaxis, have been observed both on initial exposure and with subsequent exposure including:
8.1.3.1 Rash
8.1.3.2 Hypotension
8.1.3.3 Tachycardia
8.1.3.4 Cardiac Failure
8.1.3.5 Dyspnea
8.1.3.6 Wheezing
8.1.3.7 Bronchospasm
8.1.3.8 Respiratory failure
8.1.4 During first infusion the patient must be placed on the cardiac monitor and pulse oximeter for the entire infusion. If no reaction occurs with first infusion subsequent infusions do not require the patient to be placed on the cardiac monitor and pulse oximeter.
8.1.5 Educate patient and family and document per Hospital policy.

8.2 Administration of Basiliximab:
8.2.1 Basiliximab is generally administered intravenously over 30 minutes unless otherwise specified in the order.
8.2.2 Basiliximab will be reconstituted by pharmacy and is given once a week.
8.2.3 Visibly inspect the product. If visibly opaque particles, discoloration, or other abnormalities are observed, the solution should not be used.

8.2.4 If basiliximab arrives in a syringe, then connect to current syringe pump tubing and administer per orders, flush the tubing with either D5W or Normal Saline afterwards.

8.2.5 If basiliximab arrives in a bag, then spike with secondary tubing, prime tubing with medication and infuse as a secondary medication per orders, flush the tubing with either D5W or normal saline afterwards.

8.2.6 If an infusion reaction occurs, stop the infusion and consult on service attending physician to determine treatment of reaction and to determine if further drug should be administered.

9 RELATED DOCUMENTS/FORMS

9.1 NA

10 REFERENCES


11 REVISION HISTORY

<table>
<thead>
<tr>
<th>Revision No.</th>
<th>Author</th>
<th>Description of Change(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>06</td>
<td>Sally McCollum</td>
<td>• Section 8.1.4 updated to show cardiac monitoring requirements: During first infusion the patient must be placed on the cardiac monitor and pulse oximeter for the entire infusion. If no reaction occurs with first infusion subsequent infusions do not require the patient to be placed on the cardiac monitor and pulse oximeter.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Acronyms defined throughout</td>
</tr>
</tbody>
</table>
# Signature Manifest

**Document Number:** PBMT-GEN-049  
**Title:** Administration of Basiliximab  

All dates and times are in Eastern Time.

## PBMT-GEN-049 Administration of Basiliximab

### Author

<table>
<thead>
<tr>
<th>Name/Signature</th>
<th>Title</th>
<th>Date</th>
<th>Meaning/Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sally McCollum (MOORE171)</td>
<td></td>
<td>19 Nov 2018, 09:43:20 AM</td>
<td>Approved</td>
</tr>
</tbody>
</table>

### Medical Director

<table>
<thead>
<tr>
<th>Name/Signature</th>
<th>Title</th>
<th>Date</th>
<th>Meaning/Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Kurtzberg (KURTZ001)</td>
<td></td>
<td>19 Nov 2018, 11:48:23 AM</td>
<td>Approved</td>
</tr>
</tbody>
</table>

### Quality

<table>
<thead>
<tr>
<th>Name/Signature</th>
<th>Title</th>
<th>Date</th>
<th>Meaning/Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bing Shen (BS76)</td>
<td></td>
<td>19 Nov 2018, 04:54:32 PM</td>
<td>Approved</td>
</tr>
</tbody>
</table>

### Document Release

<table>
<thead>
<tr>
<th>Name/Signature</th>
<th>Title</th>
<th>Date</th>
<th>Meaning/Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betsy Jordan (BJ42)</td>
<td></td>
<td>20 Nov 2018, 09:15:46 AM</td>
<td>Approved</td>
</tr>
</tbody>
</table>